Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cutia Therapeutics ( (HK:2487) ) has issued an announcement.
Cutia Therapeutics has scheduled a board meeting for 24 March 2026 to review and approve the annual results for the year ended 31 December 2025, and to authorize their publication. The board will also consider recommending a final dividend, if any, signaling a potential return of capital to shareholders and offering investors an early indication of the company’s financial performance and capital allocation stance.
The meeting agenda also allows for other corporate matters to be transacted, giving the board flexibility to address additional business alongside results and dividend decisions. This timetable provides the market with clarity on when key financial information and potential dividend news will be disclosed, which may influence investor sentiment and trading activity in the company’s shares.
The most recent analyst rating on (HK:2487) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.
More about Cutia Therapeutics
Cutia Therapeutics, incorporated in the Cayman Islands and listed in Hong Kong, operates in the biopharmaceutical sector, focusing on therapeutic products and related research. The company is governed by a board comprising executive, non-executive and independent non-executive directors, reflecting a standard governance structure for a Hong Kong-listed healthcare firm.
Average Trading Volume: 350,359
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.82B
For a thorough assessment of 2487 stock, go to TipRanks’ Stock Analysis page.